Safety study of BL0175 in postmenopausal women
Treatments studied
Part of Women’s health & pregnancy clinical trials.
This study tests a single dose of the investigational drug BL0175 in healthy postmenopausal women. It aims to see how safe the drug is and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who has gone through menopause (no period for at least 12 months)
- You are at least 18 years old
- You weigh at least 45 kg (99 lbs) and have a body mass index (BMI) between 18 and 35
- Your health check (blood tests, physical exam, heart EKG) shows no major problems
- You do not have a history of serious illness like heart, liver, kidney, or bleeding disorders
- You are not allergic to the study drug, alcohol, castor oil, or similar items
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how safe and tolerable a new drug, KSHN001034, is in healthy women who have gone through menopause. It involves multiple doses to see how your body processes the medicine.
This trial tests if a new drug, BL0175, is safe and effective for postmenopausal women with a certain type of advanced breast cancer (hormone receptor-positive, HER2-negative) that has progressed during or after hormone therapy. It compares different dose levels to find the best one.
This trial tests a new drug called BL0175 for women with certain types of advanced breast, ovarian, or endometrial cancer that have stopped responding to hormone therapy. The goal is to see if the drug can help shrink tumors or slow down the cancer.
This trial tests a new drug combination (SHR-A1811 with fulvestrant, with or without HS-10352) for women with advanced or metastatic breast cancer that has not been treated with systemic therapy before. It aims to see if these drugs can help slow or stop the cancer's growth.
This trial studies whether adding anlotinib (a targeted medicine) to fulvestrant (a hormone-blocking injection) can improve outcomes for people with advanced HR-positive, HER2-negative breast cancer. It focuses on safety and effectiveness when cancer has returned or progressed after hormone treatments.
This trial tests a new investigational drug called BEBT-209 combined with fulvestrant (a hormone therapy) versus placebo with fulvestrant for people with a type of breast cancer that is hormone receptor-positive and HER2-negative. It is for those whose cancer has worsened after previous hormone therapy and has spread locally or to other parts of the body.
Hear when a new Postmenopausal Women trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.